INTRODUCTION: Roux-En-Y gastric bypass (RYGB) is an alternative to reoperative fundoplication. The aim of this study was to expand long-term outcomes of patients undergoing RYGB after failed fundoplication and assess symptom resolution. METHODS: A single institution prospective study was performed of patients undergoing fundoplication takedown and RYGB between March 2007 and September 2016. Demographics, body mass index (BMI), preoperative symptoms, operative duration and findings, and postoperative outcomes were recorded. Data were assessed using standard statistical methods. RESULTS: 87 patients with failed antireflux surgery underwent RYGB. Median age 58 years (range 25-79 years). Median preoperative BMI 32.4 kg/m2 (range 21.6-50.6 kg/m2). Comorbidities included hypertension (48.3%) and diabetes (11.5%). Sixty-six patients had undergone 1 prior fundoplication, 18 had 2 prior fundoplications, and 3 had 3 prior fundoplications. At least one previous open antireflux procedure had been performed in 16.1% of patients. The most common recurrent symptoms were reflux (85.1%), dysphagia (36.7%), pain (35.6%), and regurgitation (29.9%). Median symptom-free interval from last antireflux surgery was 3 years (range 0-25 years). RYGB was performed laparoscopically in 47.1% of cases, robotically in 44.8% of cases, and open in 5.9%. Operative duration was longer in the robotic group (p = 0.04). During RYGB, 85.1% patients were found to have an associated hiatal hernia, 34.5% had intrathoracic migration of the fundoplication, 32.2% a slipped fundoplication onto proximal stomach, and 13.8% had wrap disruption. Median length of stay (LOS) was 4 days (range 1-33 days). Median follow-up was 35.8 months, 11 patients (12.6%) had recurrent reflux symptoms. Excess body weight loss (%EWL) was 80.4%. There was no mortality but 8 patients required reoperation during follow-up. CONCLUSIONS: Fundoplication takedown with RYGB was successful for long-term reflux resolution. Most can be performed via a minimally invasive approach with acceptable perioperative morbidity, symptom resolution, and the additional benefit of %EWL.
INTRODUCTION: Roux-En-Y gastric bypass (RYGB) is an alternative to reoperative fundoplication. The aim of this study was to expand long-term outcomes of patients undergoing RYGB after failed fundoplication and assess symptom resolution. METHODS: A single institution prospective study was performed of patients undergoing fundoplication takedown and RYGB between March 2007 and September 2016. Demographics, body mass index (BMI), preoperative symptoms, operative duration and findings, and postoperative outcomes were recorded. Data were assessed using standard statistical methods. RESULTS: 87 patients with failed antireflux surgery underwent RYGB. Median age 58 years (range 25-79 years). Median preoperative BMI 32.4 kg/m2 (range 21.6-50.6 kg/m2). Comorbidities included hypertension (48.3%) and diabetes (11.5%). Sixty-six patients had undergone 1 prior fundoplication, 18 had 2 prior fundoplications, and 3 had 3 prior fundoplications. At least one previous open antireflux procedure had been performed in 16.1% of patients. The most common recurrent symptoms were reflux (85.1%), dysphagia (36.7%), pain (35.6%), and regurgitation (29.9%). Median symptom-free interval from last antireflux surgery was 3 years (range 0-25 years). RYGB was performed laparoscopically in 47.1% of cases, robotically in 44.8% of cases, and open in 5.9%. Operative duration was longer in the robotic group (p = 0.04). During RYGB, 85.1% patients were found to have an associated hiatal hernia, 34.5% had intrathoracic migration of the fundoplication, 32.2% a slipped fundoplication onto proximal stomach, and 13.8% had wrap disruption. Median length of stay (LOS) was 4 days (range 1-33 days). Median follow-up was 35.8 months, 11 patients (12.6%) had recurrent reflux symptoms. Excess body weight loss (%EWL) was 80.4%. There was no mortality but 8 patients required reoperation during follow-up. CONCLUSIONS: Fundoplication takedown with RYGB was successful for long-term reflux resolution. Most can be performed via a minimally invasive approach with acceptable perioperative morbidity, symptom resolution, and the additional benefit of %EWL.
Authors: Mehraneh D Jafari; Fariba Jafari; Monica T Young; Brian R Smith; Michael J Phalen; Ninh T Nguyen Journal: Surg Endosc Date: 2013-08-13 Impact factor: 4.584
Authors: B Dallemagne; M Arenas Sanchez; D Francart; S Perretta; J Weerts; S Markiewicz; C Jehaes Journal: Br J Surg Date: 2011-06-28 Impact factor: 6.939
Authors: Paul D Colavita; Igor Belyansky; Amanda L Walters; Victor B Tsirline; Alla Y Zemlyak; Amy E Lincourt; B Todd Heniford Journal: J Gastrointest Surg Date: 2012-08-22 Impact factor: 3.452
Authors: Scott G Houghton; Lana G Nelson; James M Swain; Elizabeth M Nesset; Michael L Kendrick; Geoffrey B Thompson; Michel M Murr; Francis C Nichols; Michael G Sarr Journal: Surg Obes Relat Dis Date: 2005-08-31 Impact factor: 4.734
Authors: Dimitrios Stefanidis; Fernando Navarro; Vedra A Augenstein; Keith S Gersin; B Todd Heniford Journal: Surg Endosc Date: 2012-06-13 Impact factor: 4.584
Authors: Sudip K Ghosh; Peter J Kahrilas; Tamer Zaki; John E Pandolfino; Raymond J Joehl; James G Brasseur Journal: Am J Physiol Gastrointest Liver Physiol Date: 2005-02-03 Impact factor: 4.052
Authors: James D Luketich; Hiran C Fernando; Neil A Christie; Percival O Buenaventura; Sayeed Ikramuddin; Philip R Schauer Journal: Ann Thorac Surg Date: 2002-08 Impact factor: 4.330
Authors: Se Ryung Yamamoto; Masato Hoshino; Kalyana C Nandipati; Tommy H Lee; Sumeet K Mittal Journal: Surg Endosc Date: 2013-10-03 Impact factor: 4.584
Authors: Italo Braghetto; Owen Korn; Manuel Figueroa-Giralt; Catalina Valenzuela; Ana Maria Burgos; Carlos Mandiola; Camila Sotomayor; Eduardo Villa Journal: Arq Bras Cir Dig Date: 2022-09-09